*|MC:SUBJECT|*
up-to-date with a click!
Update March 2017
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Key publications

Other

  1. Stellaard F, Lutjohann D. The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies. Cholesterol 2017; 2017:5046294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321334
  2. Patti AM, Toth PP, Giglio RV et al. Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28317482
  3. Johal S, Jamsen KM, Bell JS et al. Do statin users adhere to a healthy diet and lifestyle? The Australian Diabetes, Obesity and Lifestyle Study. Eur J Prev Cardiol 2017; 24:621-627. http://www.ncbi.nlm.nih.gov/pubmed/?term=28326830

Add on treatments

  1. Lin X, Racette SB, Ma L et al. Ezetimibe Increases Endogenous Cholesterol Excretion in Humans. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28279967
  2. Salastekar N, Desai T, Hauser T et al. Salsalate Improves Glycemia in Overweight Persons With Diabetes Risk Factors of Stable Statin-Treated Cardiovascular Disease: a 30-month Randomized Placebo-Controlled Trial. Diabetes Obes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295931
  3. Ran D, Nie HJ, Gao YL et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291622
  4. Toyama K, Sugiyama S, Oka H et al. A Pilot Study: The Beneficial Effects of Combined Statin-exercise Therapy on Cognitive Function in Patients with Coronary Artery Disease and Mild Cognitive Decline. Intern Med 2017; 56:641-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321063
  5. Giugliano RP, Wiviott SD, Blazing MA et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291866
  6. Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. [Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease]. Kardiologiia 2015; 55:68-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294798
  7. Wani ZA, Mohapatra S, Khan AA et al. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9:270-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=28261384

Adherence

  1. Xu T, Yu X, Ou S et al. Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis. CNS drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28290082
  2. Ofori-Asenso R, Zomer E, Curtis A et al. Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28270383
  3. Tomcsanyi J. [Adherence to statins in patients with myocardial infarction in Hungary]. Orvosi hetilap 2017; 158:443-446. http://www.ncbi.nlm.nih.gov/pubmed/?term=28328244

Atherosclerosis & Imaging

  1. Nezarat N, Kim M, Budoff M. Role of Coronary Calcium for Risk Stratification and Prognostication. Current treatment options in cardiovascular medicine 2017; 19:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28275938
  2. Hecht H, Blaha MJ, Berman DS et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. Journal of cardiovascular computed tomography 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283309
  3. Emami H, Takx RA, Mayrhofer T et al. Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28330658
  4. Sun J, Zhao XQ, Balu N et al. Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC. Cardiovascular imaging 2017; 10:241-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28279371

Atorvastatin/Rosuvastatin

  1. Zhang Z, Tang L, Yu W et al. Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property. Andrologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295458
  2. Capoulade R, Chan KL, Mathieu P et al. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis 2017; 260:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319871
  3. Chen Y, Yu S, Zhang N et al. Atorvastatin prevents Angiotensin II induced myocardial hypertrophy in vitro via CCAAT/enhancer-binding protein beta. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28315329
  4. Keser T, Vuckovic F, Barrios C et al. Effects of statins on the immunoglobulin G glycome. Biochim Biophys Acta 2017; 1861:1152-1158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263871
  5. Alexandropoulos D, Bazigos GV, Doulamis IP et al. Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 89:673-680. http://www.ncbi.nlm.nih.gov/pubmed/?term=28273631
  6. Dunphy L, Morhij R, Tucker S. Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise. BMJ case reports 2017; 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302660
  7. Xie R, Yang Y, Cui W et al. Atorvastatin Can Ameliorate Left Atrial Stunning Induced by Radiofrequency Ablation for Atrial Fibrillation. Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28301729
  8. Li J, Liu J, Liang Z et al. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell death & disease 2017; 8:e2673. http://www.ncbi.nlm.nih.gov/pubmed/?term=28300827
  9. Wang Q, Zheng M, Leil T. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. CPT Pharmacometrics Syst Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28296193
  10. Kim CO, Oh ES, Kim H, Park MS. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Drug design, development and therapy 2017; 11:503-512. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260863
  11. Bertolotti M, Franchi C, Rocchi MB et al. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Societa Italiana di Medicina Interna) Study. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28299634
  12. Choi KS, Kim JM, Yi HJ et al. Dose-related effect of statins in patients with endovascular coiling or microsurgical clipping for aneurysmal subarachnoid hemorrhage: updated study-level meta-analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28293714
  13. Arbel R, Greenberg D. Using Lower Cost Statins Improves Outcomes for Normal Cholesterol Non-diabetic Patients. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277855
  14. Ran D, Nie HJ, Gao YL et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291622
  15. Kashihara Y, Ieiri I, Yoshikado T et al. Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28322941
  16. Correction to: "Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.". J Pharmacol Exp Ther 2017; 361:198. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314732
  17. Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. [Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease]. Kardiologiia 2015; 55:68-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294798
  18. Bart BY, Luchinkina EE, Gordeev IG et al. [Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin]. Kardiologiia 2016; 56:46-49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28290847
  19. Kobalava ZD, Stavtseva YV. [The Efficacy and Safety of Rosuvastatin in Patients With oronary Heart Disease]. Kardiologiia 2015; 55:80-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294722
  20. Koshelskaya OA, Vinnitskaya IV, Konko TY et al. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and With Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokynes Levels in Patients With Coronary Artery Disease and Diabetes Mellitus]. Kardiologiia 2015; 55:67-74. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294846
  21. Mikhin VP, Zhilyaeva YA, Gromnaky NI. [Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease]. Kardiologiia 2016; 56:42-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294872
  22. Panov AV, Gordeev ML, Mitrofanova LB et al. [Rosuvastatin in Coronary Bypass Surgery: Whether Only Secondary Prevention?]. Kardiologiia 2016; 56:18-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294868
  23. Samorukova EI, Adasheva TV, Zadionchenko VS, Rosliakova GA. [Pleiotropic Effects of Rosuvastatin in Patients With High Cardiovascular Risk]. Kardiologiia 2015; 55:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294912
  24. He X, Yang J, Li L et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260077
  25. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A et al. Anti-inflammatory Effects of Atorvastatin by Suppressing TRAF3IP2 and IL-17RA in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283885
  26. Yu H, Sun SQ, Gu XB et al. Atorvastatin prolongs the lifespan of radiationinduced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260074
  27. Rossi A, Inciardi RM, Rossi A et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulmonary pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263812
  28. Chang YH, Hwu DW, Kao WP, Lee YJ. Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3. The review of diabetic studies : RDS 2016; 13:212-214. http://www.ncbi.nlm.nih.gov/pubmed/?term=28278306

Basic science

  1. Dolci GS, Portela LV, Onofre de Souza D, Medeiros Fossati AC. Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2017; 151:528-538. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257738
  2. Yamada-Nomoto K, Yoshino O, Akiyama I et al. PAI-1 in granulosa cells is suppressed directly by statin and indirectly by suppressing TGF-beta and TNF-alpha in mononuclear cells by insulin-sensitizing drugs. American journal of reproductive immunology (New York, N.Y. : 1989) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28337819
  3. Zhang Z, Tang L, Yu W et al. Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property. Andrologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295458
  4. Chen Y, Yu S, Zhang N et al. Atorvastatin prevents Angiotensin II induced myocardial hypertrophy in vitro via CCAAT/enhancer-binding protein beta. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28315329
  5. Alexandropoulos D, Bazigos GV, Doulamis IP et al. Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 89:673-680. http://www.ncbi.nlm.nih.gov/pubmed/?term=28273631
  6. Mohamed MT, Abuelezz SA, Atalla SS et al. The anti-osteoporotic and anti-atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 89:1115-1124. http://www.ncbi.nlm.nih.gov/pubmed/?term=28298072
  7. Selvasudha N, Koumaravelou K. The multifunctional synergistic effect of chitosan on simvastatin loaded nanoparticulate drug delivery system. Carbohydrate polymers 2017; 163:70-80. http://www.ncbi.nlm.nih.gov/pubmed/?term=28267520
  8. Rivero J, Henriquez-Hernandez LA, L DB et al. Simvastatin down-regulates differential genetic profiles produced by organochlorine mixtures in primary breast cell (HMEC). Chemico-biological interactions 2017; 268:85-92. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263720
  9. Affandi MM, Tripathy M, Majeed A. Arginine Complexes with Simvastatin: Apparent Solubility, In Vitro Dissolution and Solid State Characterization. Current drug delivery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28322162
  10. Kida K, Tanabe K, Sasaki H et al. Release properties of atelocollagen-gelatin complexes as carriers for local administration of fluvastatin. Dent Mater J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302944
  11. Safwat S, Ishak RA, Hathout RM, Mortada ND. Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity. Drug development and industrial pharmacy 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276784
  12. Poksay KS, Sheffler DJ, Spilman P et al. Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production. Frontiers in pharmacology 2017; 8:46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28261092
  13. Sun J, Bao J, Shi Y et al. Effect of simvastatin on MMPs and TIMPs in cigarette smoke-induced rat COPD model. International journal of chronic obstructive pulmonary disease 2017; 12:717-724. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260878
  14. Luo D, Kim JH, Park C et al. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. Int J Pharm 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28330645
  15. Mendes Junior D, Domingues JA, Hausen MA et al. Study of mesenchymal stem cells cultured on a poly(lactic-co-glycolic acid) scaffold containing simvastatin for bone healing. Journal of applied biomaterials & functional materials 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291900
  16. Salem HF, Kharshoum RM, Halawa AK, Naguib DM. Preparation and optimization of tablets containing a self-nano-emulsifying drug delivery system loaded with rosuvastatin. Journal of liposome research 2017:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=28287014
  17. Chavan BB, Kalariya PD, Nimbalkar RD et al. Identification and characterization of fluvastatin metabolites in rats by UHPLC/Q-TOF/MS/MS and in silico toxicological screening of the metabolites. Journal of mass spectrometry : JMS 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295913
  18. Goto N, Okazaki K, Akasaki Y et al. A single intra-articular injection of fluvastatin-PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303595
  19. Correction to: "Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.". J Pharmacol Exp Ther 2017; 361:198. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314732
  20. Bilski P, Druzbicki K, Jenczyk J et al. Molecular and Vibrational Dynamics in a Cholesterol-Lowering Agent Lovastatin: Solid-State NMR, Inelastic Neutron Scattering and Periodic DFT Study. The journal of physical chemistry. B 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28282493
  21. He X, Yang J, Li L et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260077
  22. Yu H, Sun SQ, Gu XB et al. Atorvastatin prolongs the lifespan of radiationinduced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260074
  23. Eliasson P, Svensson RB, Giannopoulos A et al. Simvastatin and atorvastatin reduce the mechanical properties of tendon constructs in vitro and introduce catabolic changes in the gene expression pattern. PLoS One 2017; 12:e0172797. http://www.ncbi.nlm.nih.gov/pubmed/?term=28264197
  24. Gbelcova H, Rimpelova S, Ruml T et al. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Scientific reports 2017; 7:44219. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276528
  25. Yu WL, Sun TW, Qi C et al. Enhanced osteogenesis and angiogenesis by mesoporous hydroxyapatite microspheres-derived simvastatin sustained release system for superior bone regeneration. Scientific reports 2017; 7:44129. http://www.ncbi.nlm.nih.gov/pubmed/?term=28287178
  26. Zhao BJ, Xu Y, Liu YH. [Drug release from electrospun simvastatin/polycaprolactone fibrous membranes]. Shanghai kou qiang yi xue = Shanghai journal of stomatology 2016; 25:673-677. http://www.ncbi.nlm.nih.gov/pubmed/?term=28275788
  27. Yang J, Wang Y, Zhou T et al. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem cell reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28262545 

Cancer

  1. Lash TL, Riis AH, Ostenfeld EB et al. Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. American journal of epidemiology 2017:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=28338891
  2. Palumbo I, Matrone F, Montesi G et al. Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study. Anticancer research 2017; 37:1453-1457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314317
  3. Ravnskov U. Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. Br J Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28278516
  4. Li J, Liu J, Liang Z et al. Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth. Cell death & disease 2017; 8:e2673. http://www.ncbi.nlm.nih.gov/pubmed/?term=28300827
  5. Rivero J, Henriquez-Hernandez LA, L DB et al. Simvastatin down-regulates differential genetic profiles produced by organochlorine mixtures in primary breast cell (HMEC). Chemico-biological interactions 2017; 268:85-92. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263720
  6. Rodriguez-Broadbent H, Law PJ, Sud A et al. Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28340513
  7. Brower V. Pravastatin has no advantage in small-cell lung cancer. The Lancet. Oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28285843
  8. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A et al. Anti-inflammatory Effects of Atorvastatin by Suppressing TRAF3IP2 and IL-17RA in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283885
  9. Yu H, Sun SQ, Gu XB et al. Atorvastatin prolongs the lifespan of radiationinduced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. Oncology reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260074
  10. El-Hamamsy M, Elwakil H, Saad AS, Shawki MA. A Randomized Controlled Open-Label Pilot Study of Simvastatin Addition to Whole-Brain Radiation Therapy in Patients With Brain Metastases. Oncology research 2016; 24:521-528. http://www.ncbi.nlm.nih.gov/pubmed/?term=28281972
  11. Gbelcova H, Rimpelova S, Ruml T et al. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Scientific reports 2017; 7:44219. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276528

Children

  1. Dogra K, Goyal A, Khadgawat R et al. Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India. Asian journal of transfusion science 2017; 11:58-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=28316443

CVD

  1. Curtis M, Deng Y, Lee VV et al. Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. The Annals of thoracic surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318515
  2. Capoulade R, Chan KL, Mathieu P et al. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis 2017; 260:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319871
  3. Blackburn R, Osborn D, Walters K et al. Statin prescribing for people with severe mental illnesses: a staggered cohort study of 'real-world' impacts. BMJ Open 2017; 7:e013154. http://www.ncbi.nlm.nih.gov/pubmed/?term=28270387
  4. Barstow C, McDivitt JD. Cardiovascular Disease Update: Care of Patients After Coronary Artery Bypass Graft. FP essentials 2017; 454:29-33. http://www.ncbi.nlm.nih.gov/pubmed/?term=28266826
  5. Ran D, Nie HJ, Gao YL et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291622
  6. Suwa S, Ogita M, Miyauchi K et al. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321012
  7. Fujisue K, Tsujita K. Current status of lipid management in acute coronary syndrome. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28325524
  8. Emami H, Takx RA, Mayrhofer T et al. Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28330658
  9. Sun J, Zhao XQ, Balu N et al. Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC. Cardiovascular imaging 2017; 10:241-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28279371
  10. Kobalava ZD, Stavtseva YV. [The Efficacy and Safety of Rosuvastatin in Patients With oronary Heart Disease]. Kardiologiia 2015; 55:80-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294722
  11. Koshelskaya OA, Vinnitskaya IV, Konko TY et al. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and With Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokynes Levels in Patients With Coronary Artery Disease and Diabetes Mellitus]. Kardiologiia 2015; 55:67-74. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294846
  12. Panov AV, Gordeev ML, Mitrofanova LB et al. [Rosuvastatin in Coronary Bypass Surgery: Whether Only Secondary Prevention?]. Kardiologiia 2016; 56:18-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294868
  13. Rossi A, Inciardi RM, Rossi A et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulmonary pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263812

Endothelium/inflammation

  1. Zhang Z, Tang L, Yu W et al. Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property. Andrologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295458
  2. Kitagawa K, Hosomi N, Nagai Y et al. Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302952
  3. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A et al. Anti-inflammatory Effects of Atorvastatin by Suppressing TRAF3IP2 and IL-17RA in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Mol Neurobiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283885

FH

  1. Dogra K, Goyal A, Khadgawat R et al. Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India. Asian journal of transfusion science 2017; 11:58-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=28316443
  2. Bernelot Moens SJ, Neele AE, Kroon J et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28329114
  3. Yang J, Wang Y, Zhou T et al. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem cell reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28262545 

Generics

  1. Bart BY, Luchinkina EE, Gordeev IG et al. [Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin]. Kardiologiia 2016; 56:46-49. http://www.ncbi.nlm.nih.gov/pubmed/?term=28290847 

Genetics

  1. Kim CO, Oh ES, Kim H, Park MS. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Drug design, development and therapy 2017; 11:503-512. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260863
  2. Rodriguez-Broadbent H, Law PJ, Sud A et al. Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28340513
  3. Carroll C, Tappenden P, Rafia R et al. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28285379

Guidelines

  1. Bouchonville MF, Matani S, DuBroff JJ, DuBroff RJ. Are diabetes guidelines truly evidence based? Diabetes Res Clin Pract 2017; 127:70-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319804
  2. Colantonio LD, Richman JS, Carson AP et al. Performance of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations by Social Deprivation Status. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314800
  3. Okerson T, Patel J, DiMario S et al. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314797
  4. Hecht H, Blaha MJ, Berman DS et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography. Journal of cardiovascular computed tomography 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283309
  5. Shah RV, Spahillari A, Mwasongwe S et al. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28315622

LDL- related parameters

  1. Bertolotti M, Franchi C, Rocchi MB et al. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Societa Italiana di Medicina Interna) Study. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28299634
  2. Suwa S, Ogita M, Miyauchi K et al. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321012
  3. Thongtang N, Sitthananun C, Sriussadaporn S, Nitiyanant W. Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients. Journal of diabetes and metabolic disorders 2017; 16:6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28289653

Meta-analyses

  1. Salado-Font SM, Lopez-Munoz F, Povedano-Montero FJ, Labella Quesada F. Bibliometric analysis of the scientific production as regards statin use for ophthalmological symptoms of myasthenia gravis. Archivos de la Sociedad Espanola de Oftalmologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318833
  2. Xu T, Yu X, Ou S et al. Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis. CNS drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28290082
  3. Choi KS, Kim JM, Yi HJ et al. Dose-related effect of statins in patients with endovascular coiling or microsurgical clipping for aneurysmal subarachnoid hemorrhage: updated study-level meta-analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28293714
  4. Fang JX, Wang EQ, Wang W et al. The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review. Internal and emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303440
  5. Yu S, Chu Y, Li G et al. Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28320745
  6. Emami H, Takx RA, Mayrhofer T et al. Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy. JACC. Cardiovascular imaging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28330658
  7. Koshelskaya OA, Vinnitskaya IV, Konko TY et al. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and With Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokynes Levels in Patients With Coronary Artery Disease and Diabetes Mellitus]. Kardiologiia 2015; 55:67-74. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294846
  8. Chen W, Huang Z, Bi M et al. Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials. Lipids Health Dis 2017; 16:53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28288631
  9. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM : monthly journal of the Association of Physicians 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28340216
  10. Qian LJ, Gao Y, Zhang YM et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Scientific reports 2017; 7:238. http://www.ncbi.nlm.nih.gov/pubmed/?term=28331223 

Metabolic Syndrome - Diabetes

  1. Bouchonville MF, Matani S, DuBroff JJ, DuBroff RJ. Are diabetes guidelines truly evidence based? Diabetes Res Clin Pract 2017; 127:70-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319804
  2. Arbel R, Greenberg D. Using Lower Cost Statins Improves Outcomes for Normal Cholesterol Non-diabetic Patients. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277855
  3. Sun J, Zhao XQ, Balu N et al. Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC. Cardiovascular imaging 2017; 10:241-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28279371
  4. Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. [Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease]. Kardiologiia 2015; 55:68-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294798

New Treatments

  1. Baruch A, Luca D, Kahn RS et al. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28326559
  2. Bernelot Moens SJ, Neele AE, Kroon J et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28329114
  3. Millar JS, Lassman ME, Thomas T et al. Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL TG and Plasma Apolipoproteins C-II, C-III, and E. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314859
  4. Koren MJ, Sabatine MS, Giugliano RP et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291870
  5. Ridker PM, Tardif JC, Amarenco P et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28304227
  6. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28304224
  7. Carroll C, Tappenden P, Rafia R et al. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28285379
  8. Qian LJ, Gao Y, Zhang YM et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Scientific reports 2017; 7:238. http://www.ncbi.nlm.nih.gov/pubmed/?term=28331223
  9. Yang J, Wang Y, Zhou T et al. Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem cell reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28262545
  10. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9:76-91. http://www.ncbi.nlm.nih.gov/pubmed/?term=28289523 

PAD and statins

  1. Mansi IA, Frei CR, Halm EA, Mortensen EM. Association of statins with aortic, peripheral, and visceral artery aneurysm development. Vascular 2016:1708538116684942. http://www.ncbi.nlm.nih.gov/pubmed/?term=28264180 

Pleiotropic effects of statins

  1. Dolci GS, Portela LV, Onofre de Souza D, Medeiros Fossati AC. Atorvastatin-induced osteoclast inhibition reduces orthodontic relapse. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2017; 151:528-538. http://www.ncbi.nlm.nih.gov/pubmed/?term=28257738
  2. Schierwagen R, Uschner FE, Magdaleno F et al. Rationale for the use of statins in liver disease. American journal of physiology. Gastrointestinal and liver physiology 2017:ajpgi.00441.02016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28280144
  3. Zhang Z, Tang L, Yu W et al. Improvement in erectile function in a rat model of high cholesterol diet-induced atherosclerosis by atorvastatin in a manner that is independent of its lipid-lowering property. Andrologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295458
  4. Salado-Font SM, Lopez-Munoz F, Povedano-Montero FJ, Labella Quesada F. Bibliometric analysis of the scientific production as regards statin use for ophthalmological symptoms of myasthenia gravis. Archivos de la Sociedad Espanola de Oftalmologia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318833
  5. Liao KF, Cheng KC, Lin CL, Lai SW. Statin Use Correlates with Reduced Risk of Pyogenic Liver Abscess: A Population-based Case-Control Study. Basic & clinical pharmacology & toxicology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28273396
  6. Alexandropoulos D, Bazigos GV, Doulamis IP et al. Protective effects of N-acetylcystein and atorvastatin against renal and hepatic injury in a rat model of intestinal ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 89:673-680. http://www.ncbi.nlm.nih.gov/pubmed/?term=28273631
  7. Mohamed MT, Abuelezz SA, Atalla SS et al. The anti-osteoporotic and anti-atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017; 89:1115-1124. http://www.ncbi.nlm.nih.gov/pubmed/?term=28298072
  8. Gui Q, Yang Y, Zhang J. Effects of statins on the development of sepsis and organ dysfunction in hospitalized older patients in China. Braz J Infect Dis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28282509
  9. Xie R, Yang Y, Cui W et al. Atorvastatin Can Ameliorate Left Atrial Stunning Induced by Radiofrequency Ablation for Atrial Fibrillation. Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28301729
  10. Kohler-Forsberg O, Gasse C, Berk M, Ostergaard SD. Do Statins Have Antidepressant Effects? CNS drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303466
  11. Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, haemostatic factors and thrombotic risk. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28266936
  12. Andrade C. Relative to SSRI users, SSRI-statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality. Evidence-based mental health 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28283544
  13. Holzhauser L, Hovnanians N, Eshtehardi P et al. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303379
  14. Chang FM, Wang YP, Lang HC et al. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study. Hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318053
  15. Mendes Junior D, Domingues JA, Hausen MA et al. Study of mesenchymal stem cells cultured on a poly(lactic-co-glycolic acid) scaffold containing simvastatin for bone healing. Journal of applied biomaterials & functional materials 2017:0. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291900
  16. Agarwal S, Chaubey KK, Chaubey A et al. Clinical efficacy of subgingivally delivered simvastatin gel in chronic periodontitis patients. Journal of Indian Society of Periodontology 2016; 20:409-416. http://www.ncbi.nlm.nih.gov/pubmed/?term=28298823
  17. Goto N, Okazaki K, Akasaki Y et al. A single intra-articular injection of fluvastatin-PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303595
  18. Arian A, Moghadam SG, Kazemi T, Hajihosseini M. The Effects of Statins on Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Journal of research in pharmacy practice 2017; 6:27-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28331863
  19. Mikhin VP, Zhilyaeva YA, Gromnaky NI. [Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease]. Kardiologiia 2016; 56:42-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294872
  20. Ponomareva AI, Kompaniets OG, Linchak RM, Agafonova GA. [Pharmacoepidemiology of Statins in Patients With Hypertension and Dyslipidemia]. Kardiologiia 2015; 55:25-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294791
  21. Samorukova EI, Adasheva TV, Zadionchenko VS, Rosliakova GA. [Pleiotropic Effects of Rosuvastatin in Patients With High Cardiovascular Risk]. Kardiologiia 2015; 55:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294912
  22. Chen W, Huang Z, Bi M et al. Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials. Lipids Health Dis 2017; 16:53. http://www.ncbi.nlm.nih.gov/pubmed/?term=28288631
  23. He X, Yang J, Li L et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260077
  24. Yu WL, Sun TW, Qi C et al. Enhanced osteogenesis and angiogenesis by mesoporous hydroxyapatite microspheres-derived simvastatin sustained release system for superior bone regeneration. Scientific reports 2017; 7:44129. http://www.ncbi.nlm.nih.gov/pubmed/?term=28287178
  25. Wani ZA, Mohapatra S, Khan AA et al. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol 2017; 9:270-277. http://www.ncbi.nlm.nih.gov/pubmed/?term=28261384

Primary Prevention

  1. Shah RV, Spahillari A, Mwasongwe S et al. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28315622

Registry data

  1. Curtis M, Deng Y, Lee VV et al. Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. The Annals of thoracic surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318515
  2. Blackburn R, Osborn D, Walters K et al. Statin prescribing for people with severe mental illnesses: a staggered cohort study of 'real-world' impacts. BMJ Open 2017; 7:e013154. http://www.ncbi.nlm.nih.gov/pubmed/?term=28270387
  3. Punekar RS, Fox KM, Paoli CJ et al. Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. Current medical research and opinion 2017:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276256
  4. Bertolotti M, Franchi C, Rocchi MB et al. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Societa Italiana di Medicina Interna) Study. Drugs Aging 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28299634
  5. Holzhauser L, Hovnanians N, Eshtehardi P et al. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303379
  6. Chang FM, Wang YP, Lang HC et al. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study. Hepatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318053
  7. Serban MC, Colantonio LD, Manthripragada AD et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol 2017; 69:1386-1395. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302290
  8. Okerson T, Patel J, DiMario S et al. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314797
  9. Lin CM, Liao KF, Lin CL, Lai SW. Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28301063
  10. Thongtang N, Sitthananun C, Sriussadaporn S, Nitiyanant W. Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients. Journal of diabetes and metabolic disorders 2017; 16:6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28289653
  11. Hamzei E, Alavi A, Khorami Saber M, Azad M. The effect of statins on National Institutes of Health Stroke Scale (NiHSS) in Ischemic stroke. Journal of medicine and life 2015; 8:52-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28316706
  12. Hou T, Li Y, Chen W et al. Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy. Journal of neuromuscular diseases 2017; 4:77-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28269789
  13. Tomcsanyi J. [Adherence to statins in patients with myocardial infarction in Hungary]. Orvosi hetilap 2017; 158:443-446. http://www.ncbi.nlm.nih.gov/pubmed/?term=28328244
  14. Philibert C, Bres V, Jean-Pastor MJ et al. [Red yeast-rice-induced muscular injuries: Analysis of French pharmacovigilance database and literature review]. Therapie 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277227
  15. Mansi IA, Frei CR, Halm EA, Mortensen EM. Association of statins with aortic, peripheral, and visceral artery aneurysm development. Vascular 2016:1708538116684942. http://www.ncbi.nlm.nih.gov/pubmed/?term=28264180
  16. Barkas F, Elisaf M, Klouras E et al. Statin escape phenomenon: Fact or fiction? World journal of experimental medicine 2017; 7:25-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28261552

Renal Disease

  1. Olsson AG, Angelin B, Assmann G et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. Journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295777
  2. He X, Yang J, Li L et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260077
  3. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM : monthly journal of the Association of Physicians 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28340216
  4. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9:76-91. http://www.ncbi.nlm.nih.gov/pubmed/?term=28289523

Reviews

  1. Schierwagen R, Uschner FE, Magdaleno F et al. Rationale for the use of statins in liver disease. American journal of physiology. Gastrointestinal and liver physiology 2017:ajpgi.00441.02016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28280144
  2. Ravnskov U. Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. Br J Cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28278516
  3. Stellaard F, Lutjohann D. The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies. Cholesterol 2017; 2017:5046294. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321334
  4. Kohler-Forsberg O, Gasse C, Berk M, Ostergaard SD. Do Statins Have Antidepressant Effects? CNS drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303466
  5. Bianconi V, Sahebkar A, Banach M, Pirro M. Statins, haemostatic factors and thrombotic risk. Current opinion in cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28266936
  6. Nezarat N, Kim M, Budoff M. Role of Coronary Calcium for Risk Stratification and Prognostication. Current treatment options in cardiovascular medicine 2017; 19:8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28275938
  7. Bouchonville MF, Matani S, DuBroff JJ, DuBroff RJ. Are diabetes guidelines truly evidence based? Diabetes Res Clin Pract 2017; 127:70-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319804
  8. Tomlinson B, Hu M, Zhang Y et al. Alirocumab for the treatment of hypercholesterolaemia. Expert opinion on biological therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277798
  9. Arbel R, Greenberg D. Using Lower Cost Statins Improves Outcomes for Normal Cholesterol Non-diabetic Patients. Expert review of pharmacoeconomics & outcomes research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277855
  10. Barstow C, McDivitt JD. Cardiovascular Disease Update: Care of Patients After Coronary Artery Bypass Graft. FP essentials 2017; 454:29-33. http://www.ncbi.nlm.nih.gov/pubmed/?term=28266826
  11. Nissen SE. Statin Intolerance: An Elusive But Morbid Disorder. J Am Coll Cardiol 2017; 69:1396-1398. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302291
  12. Fujisue K, Tsujita K. Current status of lipid management in acute coronary syndrome. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28325524
  13. Nazir S, Lohani S, Tachamo N et al. Statin-Associated Autoimmune Myopathy: A Systematic Review of 100 Cases. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277343
  14. Malachowski SJ, Quattlebaum AM, Miladinovic B. Adverse Effects of Statins. Jama 2017; 317:1079-1080. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291886
  15. Kobalava ZD, Stavtseva YV. [The Efficacy and Safety of Rosuvastatin in Patients With oronary Heart Disease]. Kardiologiia 2015; 55:80-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294722
  16. Ponomareva AI, Kompaniets OG, Linchak RM, Agafonova GA. [Pharmacoepidemiology of Statins in Patients With Hypertension and Dyslipidemia]. Kardiologiia 2015; 55:25-31. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294791
  17. Samorukova EI, Adasheva TV, Zadionchenko VS, Rosliakova GA. [Pleiotropic Effects of Rosuvastatin in Patients With High Cardiovascular Risk]. Kardiologiia 2015; 55:32-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294912
  18. Ridker PM, Tardif JC, Amarenco P et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28304227
  19. Chrysant SG. New onset diabetes mellitus induced by statins: current evidence. Postgraduate medicine 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276790
  20. Chang YH, Hwu DW, Kao WP, Lee YJ. Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3. The review of diabetic studies : RDS 2016; 13:212-214. http://www.ncbi.nlm.nih.gov/pubmed/?term=28278306

Safety and side effects

  1. Stiles ZE, Sparks DA. Acute Extremity Compartment Syndrome Secondary to Statin-Induced Myopathy. The American surgeon 2017; 83:74-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=28316293
  2. Abd El-Hakeem EE, Kaki AM, Almazlom SA, Alsayyad AJ. Laparoscopic partial nephrectomy in a patient on simvastatin : Delayed recovery from neuromuscular blockade. Der Anaesthesist 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28265685
  3. Keser T, Vuckovic F, Barrios C et al. Effects of statins on the immunoglobulin G glycome. Biochim Biophys Acta 2017; 1861:1152-1158. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263871
  4. Dunphy L, Morhij R, Tucker S. Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise. BMJ case reports 2017; 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302660
  5. Wang Q, Zheng M, Leil T. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. CPT Pharmacometrics Syst Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28296193
  6. Fania L, Didona D, Tonanzi T et al. Simvastatin-associated dermatomyositis. Dermatologic therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28296009
  7. Kim CO, Oh ES, Kim H, Park MS. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Drug design, development and therapy 2017; 11:503-512. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260863
  8. Fang JX, Wang EQ, Wang W et al. The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review. Internal and emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303440
  9. Nissen SE. Statin Intolerance: An Elusive But Morbid Disorder. J Am Coll Cardiol 2017; 69:1396-1398. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302291
  10. Serban MC, Colantonio LD, Manthripragada AD et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol 2017; 69:1386-1395. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302290
  11. Yu S, Chu Y, Li G et al. Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28320745
  12. Kitagawa K, Hosomi N, Nagai Y et al. Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28302952
  13. Lin CM, Liao KF, Lin CL, Lai SW. Use of Simvastatin and Risk of Acute Pancreatitis: A Nationwide Case-Control Study in Taiwan. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28301063
  14. Nazir S, Lohani S, Tachamo N et al. Statin-Associated Autoimmune Myopathy: A Systematic Review of 100 Cases. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277343
  15. Olsson AG, Angelin B, Assmann G et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. Journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28295777
  16. Hou T, Li Y, Chen W et al. Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy. Journal of neuromuscular diseases 2017; 4:77-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28269789
  17. Kashihara Y, Ieiri I, Yoshikado T et al. Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28322941
  18. Goldstein LB. Adverse Effects of Statins. Jama 2017; 317:1079. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291885
  19. Thompson PD. Adverse Effects of Statins-Reply. Jama 2017; 317:1080. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291889
  20. Eliasson P, Svensson RB, Giannopoulos A et al. Simvastatin and atorvastatin reduce the mechanical properties of tendon constructs in vitro and introduce catabolic changes in the gene expression pattern. PLoS One 2017; 12:e0172797. http://www.ncbi.nlm.nih.gov/pubmed/?term=28264197
  21. Chrysant SG. New onset diabetes mellitus induced by statins: current evidence. Postgraduate medicine 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28276790
  22. Qian LJ, Gao Y, Zhang YM et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Scientific reports 2017; 7:238. http://www.ncbi.nlm.nih.gov/pubmed/?term=28331223
  23. Philibert C, Bres V, Jean-Pastor MJ et al. [Red yeast-rice-induced muscular injuries: Analysis of French pharmacovigilance database and literature review]. Therapie 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28277227
  24. Barkas F, Elisaf M, Klouras E et al. Statin escape phenomenon: Fact or fiction? World journal of experimental medicine 2017; 7:25-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28261552
  25. Li J, Zhao SP. [Renewed evaluation on statin-associated side effects]. Zhonghua xin xue guan bing za zhi 2017; 45:102-103. http://www.ncbi.nlm.nih.gov/pubmed/?term=28260313

Stroke and CNS

  1. Xu T, Yu X, Ou S et al. Statin Adherence and the Risk of Stroke: A Dose-Response Meta-Analysis. CNS drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28290082
  2. Choi KS, Kim JM, Yi HJ et al. Dose-related effect of statins in patients with endovascular coiling or microsurgical clipping for aneurysmal subarachnoid hemorrhage: updated study-level meta-analysis. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28293714
  3. Ko D, Thigpen JL, Otis JA et al. Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. Int J Cardiol 2017; 227:808-812. http://www.ncbi.nlm.nih.gov/pubmed/?term=28273786
  4. Fang JX, Wang EQ, Wang W et al. The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review. Internal and emergency medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28303440
  5. Toyama K, Sugiyama S, Oka H et al. A Pilot Study: The Beneficial Effects of Combined Statin-exercise Therapy on Cognitive Function in Patients with Coronary Artery Disease and Mild Cognitive Decline. Intern Med 2017; 56:641-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321063
  6. Hamzei E, Alavi A, Khorami Saber M, Azad M. The effect of statins on National Institutes of Health Stroke Scale (NiHSS) in Ischemic stroke. Journal of medicine and life 2015; 8:52-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28316706

Trials

  1. Curtis M, Deng Y, Lee VV et al. Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery. The Annals of thoracic surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28318515
  2. Palumbo I, Matrone F, Montesi G et al. Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study. Anticancer research 2017; 37:1453-1457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28314317
  3. Capoulade R, Chan KL, Mathieu P et al. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis 2017; 260:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=28319871
  4. Xie R, Yang Y, Cui W et al. Atorvastatin Can Ameliorate Left Atrial Stunning Induced by Radiofrequency Ablation for Atrial Fibrillation. Canadian journal of physiology and pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28301729
  5. Baruch A, Luca D, Kahn RS et al. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28326559
  6. Ran D, Nie HJ, Gao YL et al. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291622
  7. Toyama K, Sugiyama S, Oka H et al. A Pilot Study: The Beneficial Effects of Combined Statin-exercise Therapy on Cognitive Function in Patients with Coronary Artery Disease and Mild Cognitive Decline. Intern Med 2017; 56:641-649. http://www.ncbi.nlm.nih.gov/pubmed/?term=28321063
  8. Arian A, Moghadam SG, Kazemi T, Hajihosseini M. The Effects of Statins on Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Journal of research in pharmacy practice 2017; 6:27-30. http://www.ncbi.nlm.nih.gov/pubmed/?term=28331863
  9. Sun J, Zhao XQ, Balu N et al. Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC. Cardiovascular imaging 2017; 10:241-249. http://www.ncbi.nlm.nih.gov/pubmed/?term=28279371
  10. Giugliano RP, Wiviott SD, Blazing MA et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291866
  11. Koren MJ, Sabatine MS, Giugliano RP et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291870
  12. Shah RV, Spahillari A, Mwasongwe S et al. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28315622
  13. Baranova EI, Berezina AV, Melioranskaya EI, Polyakova EA. [Safety and Efficacy of Amlodipine, Lisinopril and Rosuvastatin Therapy in Patients With Metabolic Syndrome and Nonalcoholic Fatty Liver Disease]. Kardiologiia 2015; 55:68-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294798
  14. Koshelskaya OA, Vinnitskaya IV, Konko TY et al. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and With Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokynes Levels in Patients With Coronary Artery Disease and Diabetes Mellitus]. Kardiologiia 2015; 55:67-74. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294846
  15. Mikhin VP, Zhilyaeva YA, Gromnaky NI. [Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease]. Kardiologiia 2016; 56:42-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294872
  16. Panov AV, Gordeev ML, Mitrofanova LB et al. [Rosuvastatin in Coronary Bypass Surgery: Whether Only Secondary Prevention?]. Kardiologiia 2016; 56:18-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=28294868
  17. Ridker PM, Tardif JC, Amarenco P et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28304227
  18. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28304224
  19. Rossi A, Inciardi RM, Rossi A et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulmonary pharmacology & therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28263812

Women and elderly

  1. Gurwitz JH, Go AS, Fortmann SP. Use of Statins in Adults Older Than 75 Years-Reply. Jama 2017; 317:1081. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291890
  2. Stone NJ, Blum CB. Use of Statins in Adults Older Than 75 Years. Jama 2017; 317:1081. http://www.ncbi.nlm.nih.gov/pubmed/?term=28291887
  3. Ofori-Asenso R, Zomer E, Curtis A et al. Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. JMIR research protocols 2017; 6:e39. http://www.ncbi.nlm.nih.gov/pubmed/?term=28270383

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp